Peptide Schedule
Alpha-MSH (α-Melanocyte-Stimulating Hormone)13 residues (approx.)SYSMEHFRWGKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Benefits
About Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid neuropeptide produced by cleavage of proopiomelanocortin (POMC) in the pituitary gland, hypothalamus, keratinocytes, and immune cells. First characterized for its role in stimulating melanin production in melanocytes, alpha-MSH has since been recognized as a central mediator of inflammation, immune regulation, energy homeostasis, and appetite control. It signals through the melanocortin receptor family (MC1R-MC5R), G-protein coupled receptors that activate adenylyl cyclase and increase intracellular cAMP. MC1R activation on immune cells drives its potent anti-inflammatory effects, while MC4R signaling in the hypothalamus regulates satiety and energy expenditure. Alpha-MSH has demonstrated efficacy in numerous preclinical models of inflammation including colitis, arthritis, brain ischemia, organ transplant rejection, allergic inflammation, and fibrosis. Its anti-inflammatory potency exceeds many conventional agents in animal models. The discovery that the C-terminal tripeptide KPV (Lys-Pro-Val) retains anti-inflammatory signaling without melanogenic or appetite-suppressive effects has opened avenues for targeted therapeutic development. Clinically, the melanocortin pathway has been validated through FDA approval of setmelanotide (Imcivree) for MC4R-related obesity and afamelanotide (Scenesse) for erythropoietic protoporphyria, confirming the druggability of this receptor system. Native alpha-MSH remains a research-only compound due to its short half-life and broad receptor activity.
Who Should Consider Alpha-MSH (α-Melanocyte-Stimulating Hormone)
- Researchers studying inflammatory and autoimmune disease pathways
- Scientists investigating melanocortin receptor pharmacology
- Clinicians exploring anti-inflammatory peptide therapeutics
- Researchers in dermatology and pigmentation biology
- Scientists studying appetite regulation and energy homeostasis
How Alpha-MSH (α-Melanocyte-Stimulating Hormone) Works
Alpha-MSH exerts its effects primarily through melanocortin receptors (MC1R-MC5R), all of which are G-protein coupled receptors linked to stimulatory G-alpha subunits (Gs). Upon binding, alpha-MSH activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). On immune cells, MC1R activation by alpha-MSH inhibits NF-kB nuclear translocation, the master transcription factor driving inflammatory gene expression. This suppresses production of TNF-alpha, IL-1beta, IL-6, IL-8, nitric oxide, and prostaglandins while upregulating the anti-inflammatory cytokine IL-10. Alpha-MSH also inhibits neutrophil chemotaxis, reduces adhesion molecule expression on endothelial cells (ICAM-1, VCAM-1), and suppresses T-cell proliferation. In melanocytes, MC1R activation stimulates tyrosinase and melanin synthesis via MITF transcription factor upregulation. In the hypothalamus, MC4R activation suppresses appetite by modulating AgRP/NPY and POMC/CART neuronal circuits. The anti-inflammatory signaling cascade involves JAK/STAT pathway modulation, MAPK inhibition, and activation of the cholinergic anti-inflammatory pathway.
What to Expect
Establishment of dosing tolerance; measurable reduction in inflammatory biomarkers (CRP, IL-6) in research models
Observable anti-inflammatory effects in target tissue; potential mild pigmentation changes noted
Peak anti-inflammatory efficacy; sustained suppression of NF-kB-driven cytokine production
Full immunomodulatory response established; assess endpoints and determine continuation or cycling off
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 250mcg | Daily |
| Aggressive | 500mcg | Daily |
Note: Alpha-MSH is a 13-amino-acid endogenous peptide (Ac-SYSMEHFRWGKPV-NH2) derived from post-translational processing of proopiomelanocortin (POMC). It is one of the most potent endogenous anti-inflammatory mediators known, acting through melanocortin receptors MC1R through MC5R with varying affinities. The C-terminal tripeptide KPV retains much of the anti-inflammatory activity without melanogenic effects. Native alpha-MSH has an extremely short plasma half-life due to rapid enzymatic degradation, which has driven development of synthetic analogs such as afamelanotide (Scenesse) and setmelanotide (Imcivree). Research use only in its native form.
How to Inject Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Reconstitute lyophilized alpha-MSH with bacteriostatic water at the desired concentration. Inject subcutaneously into abdominal fat tissue for systemic anti-inflammatory effects. Due to the short half-life of approximately 20 minutes, multiple daily injections or continuous subcutaneous infusion may be considered in research protocols requiring sustained exposure. Intravenous administration provides faster onset but even shorter duration. Rotate injection sites to prevent local tissue irritation. Store reconstituted solution refrigerated and protect from light. Use insulin syringes for accurate low-volume dosing. Allow solution to reach room temperature before injection to minimize discomfort.
Cycling Protocol
Due to potential for melanocortin receptor desensitization with prolonged use, cycling is recommended. Monitor for skin pigmentation changes. The short half-life means effects dissipate rapidly upon discontinuation. Adjust cycle length based on research objectives and observed responses.
Pharmacokinetics
Source: Estimated ~20 minutes based on plasma clearance studies; Catania A et al., Pharmacol Rev 2004
Loading the interactive decay curve.
Side Effects
Due to broad melanocortin receptor activation, alpha-MSH may cause transient skin darkening or hyperpigmentation with repeated dosing. Appetite suppression and reduced food intake can occur through MC4R activation. Mild nausea, flushing, and fatigue have been reported in research settings. Cardiovascular effects including mild changes in heart rate or blood pressure are possible at higher doses. The short half-life limits duration of side effects but also therapeutic window. Synthetic analogs with longer half-lives carry more pronounced side effect profiles. No significant hepatotoxicity or nephrotoxicity has been observed in preclinical studies at standard research doses.
Contraindications
- Known hypersensitivity to alpha-MSH or POMC-derived peptides
- Active melanoma or history of melanoma (MC1R-driven melanocyte stimulation)
- Pregnancy or breastfeeding (insufficient safety data)
- Severe hepatic impairment affecting peptide metabolism
- Individuals with eating disorders (MC4R appetite suppression effects)
Drug Interactions
- Melanocortin receptor antagonists (e.g., agouti-related peptide, SHU9119) may block effects
- Immunosuppressants — additive immunomodulatory effects may increase infection risk
- Appetite stimulants or orexigenic agents — antagonistic effects via MC4R pathway
- Corticosteroids — overlapping anti-inflammatory mechanisms may complicate dose assessment
- CYP-metabolized drugs — no known direct interactions, but monitor in combination studies
Storage & Stability
Molecular Profile
Related Peptides
References
- Alpha-melanocyte-stimulating hormone: an emerging anti-inflammatory antimicrobial peptideReview
- Anti-inflammatory actions of the melanocortin systemReview
- The melanocortin peptide alpha-MSH: biology, clinical relevance, and therapeutic developmentReview
- Alpha-MSH and related peptides as anti-inflammatory agents: biology and clinical applicationsReview
- Protective effects of alpha-MSH in inflammation and ischemia-reperfusion injuryPubMed 11909860